GT Biopharma
GTBP
GTBP
57 hedge funds and large institutions have $12.9M invested in GT Biopharma in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 28 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
23% less capital invested
Capital invested by funds: $16.7M → $12.9M (-$3.83M)
82% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 28
Holders
57
Holding in Top 10
–
Calls
$156K
Puts
$135K
Top Buyers
| 1 | +$148K | |
| 2 | +$102K | |
| 3 | +$74K | |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$62K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$56.4K |
Top Sellers
| 1 | -$629K | |
| 2 | -$549K | |
| 3 | -$506K | |
| 4 |
Renaissance Technologies
New York
|
-$347K |
| 5 |
Two Sigma Advisers
New York
|
-$290K |